EUCTR2008-005312-41-AT进行中（未招募）不适用
Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma - Panter-study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 430
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed written informed consent obtained prior to any study-specific procedure
- •2.Age = 18 years, full contractual capability
- •3.Proven K-RAS wildtype in primary tumour or metastasis tissue
- •4.Diagnosis of metachronous metastases after complete resection (R0) of primary tumour without gross or microscopic evidence of residual disease.
- •Diagnosis of synchronous metastases after complete resection (R0) of primary tumour more than 1 month before study.
- •Diagnosis of synchronous metastases with sufficient evidence (i.e., CT scan or diagnostic laparoscopy) that both the primary tumour and liver metastases can be completely resected during the same procedure and resection of primary tumour may be delayed 3-4 months
- •5.Negative pregnancy test
- •6.Highly effective contraception during treatment and for at least 3 months thereafter in women (defined as pearl index < 1), if necessary also for partners of test persons, complete abstinence of intercourse (during study participation and follow-up time)
- •7.Planned start of study medication between 0 and 3 weeks post randomization
- •8.ECOG performance status 0 or 1 (Appendix 1)
- •9.Adequate hematology: neutrophils > 1.5 /nl, platelets > 100/nl, INR < 1.5, aPTT < 1.5 x UNL
- •10.Adequate biochemistry: total bilirubin < 1.5 x UNL, ASAT and ALAT < 5 x UNL, alkaline phosphatase < 5 x UNL, serum creatinine < 1.5 x UNL
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with any relationship of dependence to the sponsor or the investigator
- •2.Patients committed to an institution (court-ordered or by official orders)
- •3.Extrahepatic metastatic disease
- •4.Proven K-RAS mutation or unknown K-RAS mutational status in tumour tissue.
- •5.Oxaliplatin-based adjuvant chemotherapy within 1 year before randomization.
- •6.Neuropathy = grade 3 (NCI-CTC V4.0) during prior oxaliplatin-based chemotherapy.
- •7.Any prior chemotherapy for metastatic disease.
- •8.Previous treatment with EGFR antibodies.
- •9.Prior non-colorectal malignancies, except adequately treated basalioma of the skin or carcinoma in situ of the cervix.
- •10.Bleeding diathesis or coagulation disorders
- •11.Females with a positive pregnancy test (within 14 days before treatment start) or breast feeding.
- •12.Fertile women (< 2 years after last menstruation) and women of childbearing potential not willing to use effective means of contraception
- •13.History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for drug intake.
- •14.Clinically significant (i.e. active) cardiovascular disease, e.g. cerebrovascular accidents (<6 months prior to randomization), myocardial infarction (<1 year prior to randomization), Congestive heart failure (NYHA Grades III or IV), uncontrolled hypertension while receiving chronic medication, unstable angina pectoris, significant arrhythmia.
- •15.Known peripheral neuropathy, including oxaliplatin-induced neuropathy = grade 1 (NCI-CTC V4.0). Absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible.
- •16.Known DPD-deficiency (Dihydropyrimidine dehydrogenase).
- •17.Organ allografts requiring immunosuppressive therapy.
- •18.Serious non-healing wound, ulcer or bone fracture.
- •19.Serious intercurrent infections (uncontrolled or requiring treatment).
- •20.Current or recent (within 28 days prior to randomisation) treatment with another investigational drug or participation in another investigational study.
- •21.Any contraindications against study medication (including auxiliary substances).
- •22.Patients unwilling to consent to saving and propagation of pseudonymized medical data for study reasons.
研究者
相似试验
进行中（未招募）
不适用
Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma - Panter-studyresectable liver metastases of colorectal carcinoma with proven K-RAS wildtypeMedDRA version: 18.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005312-41-DERWTH Aachen University430
终止
不适用
Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study)Liver MetastasisNCT01266187RWTH Aachen University16
已完成
不适用
Pre-operative chemotherapy with FOLFOX4 in potentially resectable liver metastases from colorectal origin. Pilot phase II studypatients with liver metastasis from colon cancerJPRN-UMIN000000740OGSG30
已完成
2 期
A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver MetastasesLiver MetastasesColorectal CancerNCT01260415University Health Network, Toronto11
进行中（未招募）
不适用
Study of the effectiveness of a treatment that involves the combination chemotherapy regimen of 5-fluorouracil+Oxaliplatin+irinotecan (Folfoxiri)to a biologic antineoplatic target therapy Erbitux on the end result from treatment with Erbitux or another biologic agent bevacizumab in the patients unresectable that showing the expression of wild-type KRAS oncogeneRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTSMedDRA version: 14.1Level: LLTClassification code 10050035Term: Metastatic colon cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000840-70-ITG.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST